Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study.

Trial Profile

Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs RG 4733 (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Glioma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Mar 2013 Planned End Date changed from 1 May 2013 to 1 Jul 2014, as reported by ClinicalTrials.gov.
    • 18 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top